12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
Launched by BOEHRINGER INGELHEIM · Oct 14, 2005
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Outpatients of either sex, aged \>/= 40 years with a diagnosis of COPD (FEV1 \</= 60% predicted \[ECCS criteria\] and FEV1/FVC \</= 70%)
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winnipeg, Manitoba, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Charleston, South Carolina, United States
Birmingham, Alabama, United States
Pembroke Pines, Florida, United States
Ste Foy, Quebec, Canada
Vancouver, British Columbia, Canada
Courtice, Ontario, Canada
Wheat Ridge, Colorado, United States
Downey, California, United States
Los Angeles, California, United States
Palo Alto, California, United States
Bay Pines, Florida, United States
Clearwater, Florida, United States
Wheaton, Maryland, United States
St. Louis, Missouri, United States
New Hyde Park, New York, United States
Elizabeth City, North Carolina, United States
Dallas, Texas, United States
Hamilton, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Sherbrooke, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Patients applied
Trial Officials
Boehringer Ingelheim Study Coordinator
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials